Design Therapeutics is a biopharmaceutical company engaged the research and development of small-molecule gene targeted chimera therapeutic candidates. It offers GeneTAC, designed to selectively target expanded genetic repeat sequences, modulate gene expression either by dialing up or down mRNA transcription, and restore cellular health. The company aims to provide treatments for Friedreich ataxia, Fuchs endothelial corneal dystrophy, Huntington’s disease, and myotonic dystrophy.